ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0174

Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Abstract Number: 0175

Predicting Cost-Related Medication Non-Adherence in US Adults with Chronic Arthritis: A Machine Learning Approach
Abstract Number: 0176

Impact of Social Determinants of Health Factors on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Abstract Number: 0177

Cost-Related Medication Non-Adherence Among US Adults with Chronic Arthritis: Trends, Comparisons, and Disparities
Abstract Number: 0178

Traditional and Lupus-Specific Risk Factors for Cardiovascular Events Among Patients with Systemic Lupus Erythematosus
Abstract Number: 0179

Social Disparities and Pathology Markers at Lupus Nephritis Diagnosis Predict Worse Kidney Outcomes
Abstract Number: 0180

Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review
Abstract Number: 0181

Increased Prevalence of and Acute Hospital Events Among Medicare Systemic Lupus Erythematosus Patients Living in Socially Vulnerable Counties in the United States
Abstract Number: 0182

Impact of Neighborhood-level Child Opportunity on Disease Activity in Children with Lupus
Abstract Number: 0183

Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN)
Abstract Number: 0184

Material Need Insecurities Are Associated with Worse Patient-Reported Outcomes Among Individuals with SLE
Abstract Number: 0185

Classifying Individuals with Rheumatic Conditions as Financially Insecure Using Electronic Health Record Data and Natural Language Processing: Algorithm Derivation and Validation
Abstract Number: 0186

Retention in Rheumatology Care and on Hydroxychloroquine and SLE Outcomes by Neighborhood Disadvantage: A Medicare Cohort Study of Acute Care and Kidney Failure
Abstract Number: 0187

Advancing Health Equity with Lupus Stakeholders to Close Care Gaps and Disparities
Abstract Number: 0188

Association Between Area Deprivation Index and Organ Damage Accumulation in a Statewide Incident Lupus Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].